121 related articles for article (PubMed ID: 9626883)
61. Reduction in myocardial high energy phosphate spin lattice relaxation times using manganese.
Scholz TD
NMR Biomed; 1994 May; 7(3):137-40. PubMed ID: 8080715
[TBL] [Abstract][Full Text] [Related]
62. Physicochemical characterisation of mangafodipir trisodium.
Tirkkonen B; Aukrust A; Couture E; Grace D; Haile Y; Holm KM; Hope H; Larsen A; Lunde HS; Sjøgren CE
Acta Radiol; 1997 Jul; 38(4 Pt 2):780-9. PubMed ID: 9245974
[TBL] [Abstract][Full Text] [Related]
63. MRI measurement of hepatocyte toxicity using the new MRI contrast agent manganese dipyridoxal diphosphate, a manganese/pyridoxal 5-phosphate chelate.
Young SW; Simpson BB; Ratner AV; Matkin C; Carter EA
Magn Reson Med; 1989 Apr; 10(1):1-13. PubMed ID: 2502699
[TBL] [Abstract][Full Text] [Related]
64. Magnetic field dependence of proton relaxation rates in tissue with added Mn2+: rabbit liver and kidney.
Koenig SH; Brown RD; Goldstein EJ; Burnett KR; Wolf GL
Magn Reson Med; 1985 Apr; 2(2):159-68. PubMed ID: 3938510
[TBL] [Abstract][Full Text] [Related]
65. Manganese dipyridoxyl-diphosphate (MnDPDP) as a viability marker in patients with myocardial infarction.
Skjold A; Amundsen BH; Wiseth R; Støylen A; Haraldseth O; Larsson HB; Jynge P
J Magn Reson Imaging; 2007 Sep; 26(3):720-7. PubMed ID: 17729351
[TBL] [Abstract][Full Text] [Related]
66. T1 efficacy of EVP-ABD: a potential manganese-based MR contrast agent for hepatic vascular and tissue phase imaging.
Zuo CS; Seoane P; Lanigan T; Harnish P; Prasad PV; Storey P; Li W; Rofsky NM
J Magn Reson Imaging; 2002 Dec; 16(6):668-75. PubMed ID: 12451580
[TBL] [Abstract][Full Text] [Related]
67. Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.
Eser G; Karabacakoglu A; Karakose S; Eser C; Kayacetin E
World J Gastroenterol; 2006 Mar; 12(10):1603-6. PubMed ID: 16570354
[TBL] [Abstract][Full Text] [Related]
68. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
Tanimoto A; Kuribayashi S
Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
[TBL] [Abstract][Full Text] [Related]
69. Fractionated manganese-enhanced MRI.
Bock NA; Paiva FF; Silva AC
NMR Biomed; 2008 Jun; 21(5):473-8. PubMed ID: 17944008
[TBL] [Abstract][Full Text] [Related]
70. Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 mumol/kg body weight in detecting focal liver tumors: results of a phase III trial using an infusion technique.
Padovani B; Lecesne R; Raffaelli C; Chevallier P; Drouillard J; Bruneton JN; Lambrechts M; Gordon P
Eur J Radiol; 1996 Nov; 23(3):205-11. PubMed ID: 9003926
[TBL] [Abstract][Full Text] [Related]
71. Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI.
Rockall AG; Planche K; Power N; Nowosinska E; Monson JP; Grossman AB; Reznek RH
Neuroendocrinology; 2009; 89(3):288-95. PubMed ID: 19023191
[TBL] [Abstract][Full Text] [Related]
72. The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularization.
Ni Y; Marchal G; Zhang X; Van Hecke P; Michiels J; Yu J; Rummeny E; Lodemann KP; Baert AL
Invest Radiol; 1993 Jun; 28(6):520-8. PubMed ID: 8320070
[TBL] [Abstract][Full Text] [Related]
73. Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging.
Choi JY; Kim MJ; Kim JH; Kim SH; Ko HK; Lim JS; Oh YT; Chung JJ; Yoo HS; Lee JT; Kim KW
Eur J Radiol; 2006 Oct; 60(1):84-90. PubMed ID: 16920315
[TBL] [Abstract][Full Text] [Related]
74. Uptake of mangafodipir trisodium (MnDPDP) by hepatocellular carcinoma: correlation with unenhanced imaging findings and histopathologic features.
Chezmar JL; Redvanly RD; Sewell CW
Acad Radiol; 1996 Aug; 3 Suppl 2():S413-4. PubMed ID: 8796617
[No Abstract] [Full Text] [Related]
75. Effect of manganese dipyridoxal diphosphate on liver magnetic resonance imaging and serum bilirubin in rats with removable biliary obstruction.
Ni Y; Petré C; Lukito G; Marchal G; Grant D; Gray TJ; Baert AL
Acad Radiol; 1995 Apr; 2(4):300-5. PubMed ID: 9419566
[TBL] [Abstract][Full Text] [Related]
76. Detection of acute myocardial ischemia using first-pass dynamics of MnDPDP on inversion recovery echoplanar imaging.
Wyttenbach R; Saeed M; Wendland MF; Geschwind JF; Bremerich J; Arheden H; Higgins CB
J Magn Reson Imaging; 1999 Feb; 9(2):209-14. PubMed ID: 10077015
[TBL] [Abstract][Full Text] [Related]
77. Contrast-enhanced magnetic resonance imaging of the liver with Mn-DPDP for known or suspected focal hepatic disease.
Bernardino ME; Young SW; Lee JK; Weinreb J
Invest Radiol; 1991 Nov; 26 Suppl 1():S148-9; discussion S150-5. PubMed ID: 1808113
[No Abstract] [Full Text] [Related]
78. A multinuclear MR study of Gd-EOB-DTPA: comprehensive preclinical characterization of an organ specific MRI contrast agent.
Vander Elst L; Maton F; Laurent S; Seghi F; Chapelle F; Muller RN
Magn Reson Med; 1997 Oct; 38(4):604-14. PubMed ID: 9324328
[TBL] [Abstract][Full Text] [Related]
79. The 31P NMR visibility of ATP in perfused rat liver remains about 90%, unaffected by changes of metabolic state.
Masson S; Quistorff B
Biochemistry; 1992 Aug; 31(33):7488-93. PubMed ID: 1510935
[TBL] [Abstract][Full Text] [Related]
80. Intraoperative contrast-enhanced MR-imaging as predictor of tissue damage during cryoablation of porcine liver.
Mala T; Frich L; Aurdal L; Clausen OP; Edwin B; Soreide O; Gladhaug I
Magn Reson Imaging; 2003 Sep; 21(7):733-40. PubMed ID: 14559337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
